Cheuk Ying Vanessa Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Cheuk Ying Vanessa Li has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Amy Hai Yan Chan
The University of Auckland
2 shared publications - Chuenjid Kongkaew
Centre for Safety and Quality in Health, Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand
2 shared publications - Joseph Edgar Blais
The University of Hong Kong
2 shared publications - Wenfang Zhong
Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China
2 shared publications
Latest Publications
- 19 June 2026
- Published by Wolters Kluwer Health in JBI Evidence Synthesis
Completeness of EMERGE guideline reporting in observational studies of PCSK9 inhibitor medication adherence: a study within a systematic review
Objectives: The objective of this study within a review was to assess the completeness of EMERGE (ESPACOMP Medication Adherence Reporting Guideline) item reporting in observational studies included in a systematic review assessing proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor medication adherence in clinical practice. Secondary objectives were to compare the completeness of reporting between studies that explicitly aimed to investigate medication adherence and those that did not, and to identify the relevance of these findings for other systematic reviews. Introduction: The International Society for Medication Adherence published the EMERGE in 2018. Although EMERGE aims to improve and standardize the reporting of research on medication adherence, the extent to which the EMERGE guideline is followed is unknown. Methods: This study within a review included 52 observational studies published after 2018 as full-length articles in the host systematic review. Completeness of reporting for each minimum and additional EMERGE item was categorized as completely reported, incompletely reported, not reported, or not applicable. Studies were grouped according to whether their primary aim was to investigate medication adherence (Group 1) or not (Group 2). The completeness of reporting each EMERGE item was compared between groups using Fisher’s exact test. Additionally, the proportion of completely reported items was compared between the groups using the t-test and Mann-Whitney U test. Results: Among the 4 minimum EMERGE items, item 1d (Describe results for the medication adherence phase) was the most often completely reported (80.8%), while item 1b (Provide a precise operation definition) was the least completely reported (38.5%). Among the additional 17 EMERGE items, item 5b (State whether medication adherence was an eligibility criterion) was completely reported in 98.1% of studies, whereas item 5c (Describe routine care related to the management of medication adherence) was the least frequently reported. Twenty (38.5%) studies were categorized into Group 1 and 32 (61.5%) into Group 2. For all EMERGE items, minimum items, and additional items, the mean proportion of completely reported items in Group 1 was higher than that in Group 2 ( P <0.001). Conclusion: Our findings suggest limited application of EMERGE among authors and journals publishing observational studies on PCSK9 inhibitor medication adherence. Strengthening the visibility and application of EMERGE may enhance the consistency of methodological reporting in future studies of medication adherence. Review registration: SWAR Store https://www.qub.ac.uk/sites/TheNorthernIrelandNetworkforTrialsMethodologyResearch/FileStore/SWARFileStore/SWAR50%20Joseph%20Edgar%20Blais%20(2024%20AUG%2001%201402).pdf (SWAR50)
- 19 June 2026
- Published by Wolters Kluwer Health in JBI Evidence Synthesis
Completeness of EMERGE guideline reporting in observational studies of PCSK9 inhibitor medication adherence: a study within a systematic review
Objectives: The objective of this study within a review was to assess the completeness of EMERGE (ESPACOMP Medication Adherence Reporting Guideline) item reporting in observational studies included in a systematic review assessing proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor medication adherence in clinical practice. Secondary objectives were to compare the completeness of reporting between studies that explicitly aimed to investigate medication adherence and those that did not, and to identify the relevance of these findings for other systematic reviews. Introduction: The International Society for Medication Adherence published the EMERGE in 2018. Although EMERGE aims to improve and standardize the reporting of research on medication adherence, the extent to which the EMERGE guideline is followed is unknown. Methods: This study within a review included 52 observational studies published after 2018 as full-length articles in the host systematic review. Completeness of reporting for each minimum and additional EMERGE item was categorized as completely reported, incompletely reported, not reported, or not applicable. Studies were grouped according to whether their primary aim was to investigate medication adherence (Group 1) or not (Group 2). The completeness of reporting each EMERGE item was compared between groups using Fisher’s exact test. Additionally, the proportion of completely reported items was compared between the groups using the t-test and Mann-Whitney U test. Results: Among the 4 minimum EMERGE items, item 1d (Describe results for the medication adherence phase) was the most often completely reported (80.8%), while item 1b (Provide a precise operation definition) was the least completely reported (38.5%). Among the additional 17 EMERGE items, item 5b (State whether medication adherence was an eligibility criterion) was completely reported in 98.1% of studies, whereas item 5c (Describe routine care related to the management of medication adherence) was the least frequently reported. Twenty (38.5%) studies were categorized into Group 1 and 32 (61.5%) into Group 2. For all EMERGE items, minimum items, and additional items, the mean proportion of completely reported items in Group 1 was higher than that in Group 2 ( P <0.001). Conclusion: Our findings suggest limited application of EMERGE among authors and journals publishing observational studies on PCSK9 inhibitor medication adherence. Strengthening the visibility and application of EMERGE may enhance the consistency of methodological reporting in future studies of medication adherence. Review registration: SWAR Store https://www.qub.ac.uk/sites/TheNorthernIrelandNetworkforTrialsMethodologyResearch/FileStore/SWARFileStore/SWAR50%20Joseph%20Edgar%20Blais%20(2024%20AUG%2001%201402).pdf (SWAR50)
- Top Cited PapersOpen Access
- 17 April 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (5) , 102733
Adherence to PCSK9 Inhibitors in Clinical Practice
- 17 April 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (5) , 102733
Top Cited PapersOpen AccessAdherence to PCSK9 Inhibitors in Clinical Practice